Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon Jun 25, 2018 7:14pm
144 Views
Post# 28227021

posted on TMX

posted on TMX
roMIS Neurosciences Inc., Treating the Root Cause of Alzheimer's, CEO Clip Video

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2018) - Dr. Elliot Goldstein, President & CEO of ProMIS Neurosciences speaks on the company's developing treatments for Alzheimer's and other neurodegenerative diseases.

 

If you cannot view the video above, please visit:
https://www.b-tv.com/promis-neurosciences-ceo-clip-90sec-3/

ProMIS Neurosciences Inc. is being featured on CBC's Documentary Channel the weeks of June 25 — July 8, 2018 Monday through Friday, throughout the day and evenings.

ProMIS Neurosciences Inc.: (TSXPMN)

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts.

promisneurosciences.com

About CEO Clips:

CEO Clips is the largest library of publicly traded company CEO videos in the US and Canada.  These 90 second video profiles broadcast on national TV and are distributed online on top financial portals including: Thomson Reuters, BNN.ca, and Stockhouse.com.  They are also disseminated via a video news release to several financial portals including Globe Investor, OTC Markets, TMX Money, and The National Post.

BTV — Business Television/CEO Clip Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com

 

 

 

Bullboard Posts